Citation:Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al 2016
From Cancer Guidelines Wiki
Citation
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016 Sep;17(9):1248-60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27480103.
Critical appraisals
Compare quality appraisals for each clinical question
- [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span>»]] (compare critical appraisals)
- [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?</span></span></span></span>»]] (compare critical appraisals)